



Healing today. Curing tomorrow.

Contacts:
Barry Jenkins, CFO
Emily Browning, Marketing Manager
678-578-0103

Porter, LeVay & Rose, Inc.
Marlon Nurse, VP, Investor Relations
Bill Gordon, SVP, Media Relations
212-564-4700

FOR IMMEDIATE RELEASE

-SANUWAVE'S PACE™ SHOWS PROMISE IN STIMULATING AUTOGENOUS SOURCES OF PROGENITOR/STEM CELLS FOR HARVEST AND RE-TRANSPLANTATION IN BONE TISSUE ENGINEERING-

-Orthopedic Tissue Regeneration Research Presented at Bone-Tec Congress by Dr. Myron Spector -

ALPHARETTA, GA, October 13, 2009 – SANUWAVE, Inc., (OTC BB: RBME) (www.sanuwave.com), an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reported that scientific findings titled "Extracorporeal Shock Wave Stimulation of Osteoprogenitor Cells" were presented at the 2009 International Bone-Tissue-Engineering Congress ("Bone-Tec") in Hannover, Germany, which was held October 9-11, 2009.

Dr. Myron Spector, PhD, Professor of Orthopaedic Surgery (Biomaterials) at Harvard Medical School, Director of Orthopaedic Research at Brigham and Women's Hospital and Director of Tissue Engineering at VA Boston Healthcare System, was an invited guest speaker at the Conference. The Bone-Tec Congress featured an international scientific forum to discuss progresses in modern bone tissue regeneration and extended a worldwide network to exchange findings on the latest developments.

Dr. Spector's team employed SANUWAVE's Pulsed Acoustic Cellular Expression (PACE™) technology in pre-clinical research to create autogenous sources of stem cells for bone tissue engineering. Results support the proposition that PACE™ could be employed as a non-invasive technique to cause proliferation and thickening of the cambium layer of the femur's periosteum for the subsequent intraoperative harvesting of progenitor stem cells days later for bone or cartilage regeneration.

PACE™ stimulated a dramatic proliferation and thickening (up to 10 fold) of osteoprogenitor stem cells, precursors to bone and cartilage cells, in the cambium layer of the periosteum in the femur of the adult rats within 4 days. Neovascularization and new bone formation within the thickened periosteum were also evident after 4 days.

Dr. Spector said, "This research has shown great potential. Through more study, this technology could further advance tissue engineering autologous transplant techniques towards clinical applications such as bone reconstruction and cartilage defect repair."

-more-

Christopher M. Cashman, President and CEO of SANUWAVE said, “We are excited about the preliminary research that Dr. Spector and his team have conducted on our PACE™ technology. The procedure could have meaningful use in clinical applications, whereby a patient’s own osteoprogenitor cells could be harvested and reimplanted for procedures such as bone fusion, joint reconstruction and cartilage repair. In clinical application, stimulating a large amount of a patient’s own cells for harvest and reuse elsewhere in the body may have the added benefit of reducing the need for anti-rejection drug regimens. Further studies are needed to confirm that the proliferated cambium stem cells maintain their ability to differentiate into bone and cartilage cells.”

Mr. Cashman concluded, “Dr. Spector’s research is quite exciting and supports our efforts to further develop our technology for multiple regenerative medicine uses, in addition to SANUWAVE’s IDE clinical trial that is in progress for diabetic foot ulcers.”

About SANUWAVE®, Inc.

SANUWAVE, Inc. (www.sanuwave.com) is an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area for the repair and regeneration of tissue, musculoskeletal and vascular structures. SANUWAVE’s portfolio of products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body’s normal healing processes and regeneration. SANUWAVE intends to apply its Pulsed Acoustic Cellular Expression (PACE™) technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE™, is CE marked for treatment of the skin and subcutaneous soft tissue and is currently involved in an FDA-approved Investigation Device Exemption trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE designs, manufactures, markets and services its products worldwide and believes it has already demonstrated that this technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through it’s U.S Class III PMA approved Ossatron® device and in the stimulation of bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its Ossatron® and Evotron® devices in Europe. For more information about the dermaPACE™ trial, please visit www.dermapace.com.

Safe Harbor Statement

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

#####